Objectives: Over the past decade, some publications have reported that Immunoscore was associated with the prognosis of several cancers. To better understand this issue, we conducted this pooled analysis.

Methods: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from their inceptions to 15 May 2019 to identify relevant articles. The pooled hazard ratio (HR) and 95% confidence interval (CI) was estimated for overall survival, disease-free survival, and disease-specific survival.

Results: A total of 26 cohort studies with 10,328 patients involving eight cancer specialties were evaluated mainly by the consensus Immunoscore. The pooled analysis indicated that a lower Immunoscore was associated with a poor overall survival (HR 2.23, 95% CI 1.58, 2.70), disease-free survival (HR 2.40, 95% CI 1.96, 2.49), and disease-specific survival (HR 2.81, 95% CI 2.10, 3.77) for all cancers. The same convincing results were found in colorectal cancer, gastric cancer, and non-small cell lung cancer (especially the consensus Immunoscore for colon cancer). In five other types of cancer the results were similar, but the sample sizes were limited.

Conclusions: These findings support that Immunoscore is significantly associated with the prognosis of patients with cancer. It provides a reliable estimate of the risk of recurrence in patients with colon cancer. However, more high-quality studies are necessary to assess the prognostic value of Immunoscore in non-colon cancers.

目标：在过去十年中，一些出版物报道了 Immunoscore 与几种癌症的预后相关。为了更好地理解这个问题，我们进行了这个汇总分析。

方法：我们系统地搜索了 PubMed、Embase、Web of Science 和 Cochrane 图书馆，从它们成立到 2019 年 5 月 15 日，以确定相关文章。估计总生存期、无病生存期和疾病特异性生存期的汇总风险比 (HR) 和 95% 置信区间 (CI)。

结果：主要通过共识 Immunoscore 对涉及 8 个癌症专科的 10,328 名患者的 26 项队列研究进行了评估。汇总分析表明，较低的 Immunoscore 与较差的总生存期 (HR 2.23, 95% CI 1.58, 2.70)、无病生存期 (HR 2.40, 95% CI 1.96, 2.49) 和疾病特异性生存期 (HR 2.81, 95% CI 2.10, 3.77) 适用于所有癌症。在结直肠癌、胃癌和非小细胞肺癌（尤其是针对结肠癌的共识免疫评分）中发现了同样令人信服的结果。在其他五种癌症中，结果相似，但样本量有限。

结论：这些发现支持 Immunoscore 与癌症患者的预后显着相关。它提供了对结肠癌患者复发风险的可靠估计。然而，需要更多高质量的研究来评估 Immunoscore 在非结肠癌中的预后价值。